98%
921
2 minutes
20
Objective: Due to the lack of resources for culture and antibiotic susceptibility testing in most underdeveloped countries, puerperal sepsis is treated empirically with a wide range of antibiotics. Empirical treatment, on the other hand, does not ensure treatment effectiveness and may even contribute to antibiotic resistance. So, we studied cases of puerperal sepsis, its socio-demographic factors, bacterial isolates, and antibiotic sensitivity in a tertiary health center.
Material And Methods: This was a cross-sectional study conducted at the obstetrics and gynecology department of a tertiary health center in India from April 2019 to September 2020. During this time, all patients with sepsis who met the criteria for inclusion were included. After granting an informed written consent, the subjects were registered on a pre-designed proforma.
Results: There were 2,049 obstetrical admissions throughout this period, with 106 (5.1%) of these having puerperal sepsis. The majority of these women (58.7%) were between the ages of 21 and 30, were multiparous (96.5%), and unbooked. Fever 104 (98.1%) was the most prevalent clinical characteristic, whereas wound gape was the most common consequence (47.1%). was the most common organism found in various cultures. Many organisms were shown to be multidrug-resistant and sensitive to gentamycin and amikacin.
Conclusion: wasthe most common cause of puerperal sepsis in this investigation. Because the causal agents of puerperal sepsis and their antibiotic sensitivity patterns change over time, positive blood culture and antibiotic susceptibility of the isolates are the best guides for selecting the optimum antimicrobial therapy for treating sepsis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730957 | PMC |
http://dx.doi.org/10.4103/jfmpc.jfmpc_2419_21 | DOI Listing |
BMC Pregnancy Childbirth
September 2025
Collage of Medicine and Health Science, Jigjiga University, Jigjiga, Somali Regional State, Ethiopia.
Introduction: Puerperal sepsis is a significant public health concern in low-resource settings, including Ethiopia, where it is a major contributor to maternal mortality, accounting for 13% of maternal deaths. We investigated the determinants of puerperal sepsis among mothers who give birth at Jigjiga Public Hospitals, Somali Regional State, Eastern Ethiopia.
Methods: A facility-based unmatched case-control design was employed, with a sample size of 226 (76 cases and 151 controls).
BMC Pregnancy Childbirth
August 2025
Department of Obstetrics and Gynaecology, University College Hospital, Ibadan, Nigeria.
Background: Postpartum maternal morbidity or mortality is one of the common unexpected outcomes of childbirth, hence postnatal care is critical to reducing it. This study assessed the parturients' knowledge of postpartum warning signs and complications in a tertiary health facility at Ibadan, Nigeria.
Methods: This was a cross-sectional study among 450 parturients using a semi-structured self-administered questionnaire to assess their knowledge of postpartum warning signs and complications.
Front Cell Infect Microbiol
August 2025
Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de Mexico, Mexico.
J Family Med Prim Care
July 2025
Department of Obstetrics and Gynaecology, GSVM Medical College, Kanpur, Uttar Pradesh, India.
Context: The incidence rate of puerperal infection caused by uncommon pathogenic bacteria has risen. Thus, we sought to analyse uterine flora in patients of elective and non-elective caesarean section.
Aims: (1) To compare uterine flora in elective and non-elective caesarean section.
Intrapartum azithromycin prophylaxis reduced maternal infections but showed no effect on neonatal sepsis and mortality. Although antibiotic exposure may indirectly alter the mycobiota (community of fungi that live in a given environment), there is no data available on how intrapartum azithromycin impacts gut mycobiota development. We hereby assess the impact of intrapartum azithromycin on gut mycobiota development from birth to the age of three years, by ITS2 gene profiling of rectal samples from 102 healthy Gambian infants selected from a double-blind randomized placebo-controlled clinical trial (PregnAnZI-2 - ClinicalTrials.
View Article and Find Full Text PDF